The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Open accessAbstract
Purpose: Phase II trials with biochemotherapy (BCT) have shown encouraging response rates in metastatic melanoma, and meta-analyses and one phase III trial have suggested a survival benefit. In an effort to determine the relative efficacy of BCT compared with chemotherapy alone, a phase III trial was performed within the United States Intergroup. Patients and Methods: Patients were randomly assigned to receive cisplatin, vinblastine, and dacarbazine (CVD) either alone or concurrent with interleukin-2 and interferon alfa-2b (BCT). Treatment cycles were repeated at 21-day intervals for a maximum of four cycles. Tumor response was assessed after cycles 2 and 4, then every 3 months. Results: Four hundred fifteen patients were enrolled, and 395 patients (CVD, n = 195; BCT, n = 200) were deemed eligible and assessable. The two study arms were well balanced for stratification factors and other prognostic factors. Response rate was 19.5% for BCT and 13.8% for CVD (P = .140). Median progression-free survival was significantly longer for BCT than for CVD (4.8 v 2.9 months; P = .015), although this did not translate into an advantage in either median overall survival (9.0 v 8.7 months) or the percentage of patients alive at 1 year (41% v 36.9%). More patients experienced grade 3 or worse toxic events with BCT than CVD (95% v 73%; P = .001). Conclusion: Although BCT produced slightly higher response rates and longer median progression-free survival than CVD alone, this was not associated with either improved overall survival or durable responses. Considering the extra toxicity and complexity, this concurrent BCT regimen cannot be recommended for patients with metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
Sasse, A. D., Sasse, E. C., Clark, L. G., Ulloa, L., & Clark, O. A. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005413.pub2 · Cited by 131
RetractedKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Self-citationAtkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Self-citationEton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.044 · Cited by 370
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
Ives, N. J., Stowe, R. L., Lorigan, P., & Wheatley, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0253 · Cited by 284
Keilholz, U., Conradt, C., Legha, S. S., Khayat, D., Scheibenbogen, C., Thatcher, N., Goey, S. H., Gore, M., Dorval, T., Hancock, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2921 · Cited by 194
Keilholz, U., Goey, S. H., Punt, C. J., Proebstle, T. M., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Liénard, D., Enk, A., Dummer, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2579 · Cited by 193
Keilholz, U., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., Thomas, J., Proebstle, T. M., Schmittel, A., Schadendorf, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.202 · Cited by 165
Cytokine-Based Therapy and Biochemotherapy for Advanced Melanoma
Atkins, M. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2503 · Cited by 149
Self-citation
Cited by
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Guidelines of care for the management of primary cutaneous melanoma
Bichakjian, C. K., Halpern, A. C., Johnson, T. M., Foote Hood, A., Grichnik, J. M., Swetter, S. M., Tsao, H., Barbosa, V. H., Chuang, T.-Y., Duvic, M., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.04.031 · Cited by 616
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0190 · Cited by 582
Self-citationRole of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Metadata
- Authors
- Atkins, M. B., Hsu, J., Lee, S., Cohen, G. I., Flaherty, L. E., Sosman, J. A., Sondak, V. K., & Kirkwood, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-12-10
- Volume
- 26
- Issue
- 35
- Pages
- 5748-5754
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2027567030
- Cited by
- 320
- References
- 18
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. https://app.cochat.ai/papers/10.1200/jco.2008.17.5448
- The paper
- Atkins, M. B., Hsu, J., Lee, S., Cohen, G. I., Flaherty, L. E., Sosman, J. A., Sondak, V. K., & Kirkwood, J. M. (2008). Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.5448
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.